Bryce Point Capital, LLC Denali Therapeutics Inc. Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 20,550 shares of DNLI stock, worth $427,851. This represents 0.12% of its overall portfolio holdings.
Number of Shares
20,550Holding current value
$427,851% of portfolio
0.12%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
238Shares Held
121MCall Options Held
60.6KPut Options Held
48.4K-
Black Rock Inc. New York, NY13.2MShares$274 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$256 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$250 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA9.85MShares$205 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$165 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.79B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...